| Literature DB >> 27036115 |
Jemima A Frimpong1, Thomas D'Aunno2.
Abstract
BACKGROUND: Health care organizations do not adopt best practices as often or quickly as they merit. This gap in the integration of best practices into routine practice remains a significant public health concern. The role of program managers in the adoption of best practices has seldom been investigated.Entities:
Keywords: Adoption; Best practices; Hepatitis C (HCV); Management; Opioid treatment programs; Program managers; Substance use disorder treatment
Mesh:
Year: 2016 PMID: 27036115 PMCID: PMC4818491 DOI: 10.1186/s13011-016-0057-2
Source DB: PubMed Journal: Subst Abuse Treat Prev Policy ISSN: 1747-597X
Characteristics of Opioid Treatment Programs (OTPs)
| Full Sample | 2005 | 2011 | ||
|---|---|---|---|---|
| (N=383) | (N=187) | (N=196) | p-value* | |
| Dependent Variables | ||||
| Any HCV testing | 0.000 | |||
| HCV testing (on-site or off-site) | 81.7 | 73.3 | 89.8 | |
| No HCV testing | 18.3 | 26.7 | 10.2 | |
| On-site vs. off-site HCV testing+ | 0.000 | |||
| On-site HCV testing | 52.7 | 72.3 | 37.5 | |
| Off-site HCV testing only | 47.3 | 27.7 | 62.5 | |
| Predictor variables | ||||
| Director race/ethnicity | ||||
| African-American | 14.9 | 14.4 | 15.3 | 0.812 |
| Other race/ethnicity | 8.4 | 11.2 | 5.6 | 0.047 |
| White | 76.7 | 74.7 | 79.1 | 0.313 |
| Director age (mean, SD) | 49.7 (9.6) | 48.4 (8.5) | 51 (10.4) | 0.009 |
| Director gender | 0.354 | |||
| Female | 55.3 | 52.9 | 57.6 | |
| Male | 44.7 | 47.1 | 42.4 | |
| Director education | 0.156 | |||
| Post-graduate training or more | 70.8 | 67.4 | 74.0 | |
| College or less | 29.2 | 32.6 | 26.0 | |
| Director sources of information (mean, SD) | 3.2 (0.5) | 3.3 (0.5) | 3.1 (0.5) | 0.001 |
| Director support of preventive services (mean, SD) | 3.9 (0.9) | 3.7 (1.0) | 4.0 (0.9) | 0.004 |
| Control variables | ||||
|
| ||||
| Percent African-American patients | 22.3 (24.9) | 25.5 (26.5) | 19.3 (22.9) | 0.015 |
| Percent Hispanic / Latino patients | 16.4 (21.2) | 17.9 (22.7) | 15.0 (19.7) | 0.189 |
| Percent female patients | 41.3 (13.6) | 39.9 (15.8) | 42.7 (11.0) | 0.039 |
| Percent persons who inject drugs | 42.4 (29.8) | 44.8 (30.9) | 40.2 (28.6) | 0.133 |
|
| ||||
| CARF accreditation | 0.165 | |||
| Yes | 49.1 | 45.5 | 52.5 | |
| No | 50.9 | 54.5 | 47.5 | |
| Ownership | 0.150 | |||
| Public | 14.1 | 17.6 | 10.7 | |
| Private for-profit | 37.9 | 36.4 | 39.3 | |
| Private not-for-profit | 48.0 | 46.0 | 50.0 | |
| Method of treatment | 0.000 | |||
| Both (Meth + Bup) | 57.2 | 68.0 | 47.0 | |
| Buprenorphine only (Bup) | 24.3 | 19.2 | 29.1 | |
| Methadone only (Meth) | 18.5 | 12.8 | 23.9 | |
| Staff - patient ratio (mean, SD) | 0.04 (0.03) | 0.04 (0.04) | 0.05 (0.03) | 0.025 |
| Prior authorization (mean, SD) | 22.32 (33.8) | 19.20 (31.9) | 25.30 (35.3) | 0.078 |
| Revenue from federal sources | 0.004 | |||
| At least 1% | 28.5 | 37.9 | 21.5 | |
| None | 71.5 | 62.1 | 78.5 | |
| Revenue from private insurance | 0.142 | |||
| At least 1% | 42.3 | 41.1 | 44.3 | |
| None | 57.7 | 58.8 | 55.6 |
Continuous data are mean ± Standard Deviation (SD). Categorical data are percentage
+Among OTPs that offer any HCV testing; n = 313 OTPs
*Denotes significant differences (p<. 05) between 2005 and 2011
Offer of any HCV testing services (offer of either on-site or off-site HCV testing) in Opioid Treatment Programs
| (Any HCV testing vs. No testing) | |
|---|---|
| OR (95% CI) | |
| Predictor variables | |
| Director race/ethnicity | |
| African-American | 1.98 (0.65, 5.96) |
| Other race/ethnicity | 0.42 (0.13, 1.27) |
| White | 1† |
| Director age | 1.01 (0.97, 1.03) |
| Director gender | |
| Female | 0.67 (0.37 1.18) |
| Male | 1† |
| Director education | |
| Post-graduate training or more | 0.57 (0.28, 1.16) |
| College or less | 1† |
| Director sources of information | 1.50 (0.87, 2.58) |
| Director support of preventive services | 1.39 (1.02, 1.90)* |
| Control variables | |
|
| |
| Percent African-American patients | 0.99 (0.97, 1.00)^ |
| Percent Hispanic / Latino patients | 1.03 (1.00, 1.04)* |
| Percent female patients | 0.99 (0.96, 1.00) |
| Percent persons who inject drugs | 1.00 (0.99, 1.01) |
|
| |
| CARF accreditation | |
| Yes | 1.53 (0.75, 3.10) |
| No | 1† |
| Ownership | |
| Public | 1.10 (0.43, 2.76) |
| Private for-profit | 1.12 (0.53, 2.34) |
| Private not-for-profit | 1† |
| Method of treatment | |
| Both (Meth + Bup) | 6.41 (1.69, 24.1)* |
| Buprenorphine only (Bup) | 1.32 (0.58, 2.99) |
| Methadone only (Meth) | 1† |
| Staff - patient ratio | 1.34 (0.91, 1.94) |
| Prior authorization | 1.00 (0.98, 1.00) |
| Revenue from federal sources | |
| At least 1% | 1.40 (0.71, 2.73) |
| None | 1† |
| Revenue from private insurance | |
| At least 1% | 0.67 (0.33, 1.33) |
| None | 1† |
| Year | |
| 2005 | 0.30 (0.15, 0.58)*** |
| 2011 | 1† |
A total of 383 OTPs were included in the analysis
Ninety-five percent confidence intervals estimated with robust standard errors
† Reference category; OR, Odds ratio; CI, Confidence interval
^p< 0.10. *p < 0.05. **p < 0.01.
Offer of on-site HCV testing services among Opioid Treatment Programs offering any HCV testing (either on-site or off-site)
| (On-site vs. Off-site testing) | |
|---|---|
| OR (95% CI) | |
| Predictor variables | |
| Director race/ethnicity | 1† |
| African-American | 2.76 (1.03, 7.35)* |
| Other race/ethnicity | 0.66 (0.19, 2.27) |
| White | 1† |
| Director age | 0.97 (0.94, 1.00)^ |
| Director gender | |
| Female | 1.17 (0.65, 2.07) |
| Male | 1† |
| Director education | |
| Post-graduate training or more | 1.04 (0.55, 1.95) |
| College or less | 1† |
| Director sources of information | 2.35 (1.39, 3.97)** |
| Director support of preventive services | 1.06 (0.78, 1.45) |
| Control variables | |
|
| |
| Percent African-American patients | 0.99 (0.97, 1.00) |
| Percent Hispanic / Latino patients | 1.01 (0.99, 1.02) |
| Percent female patients | 1.01 (0.99, 1.03) |
| Percent persons who inject drugs | 0.99 (0.98, 1.00) |
|
| |
| CARF accreditation | |
| Yes | 0.63 (0.31, 1.24) |
| No | 1† |
| Ownership | |
| Public | 3.05 (1.20, 7.72)* |
| Private for-profit | 1.32 (0.62, 2.80) |
| Private not-for-profit | 1† |
| Method of treatment | |
| Both (Meth + Bup) | 2.10 (0.98, 4.48)^ |
| Buprenorphine only (Bup) | 0.14 (0.05, 0.33)*** |
| Methadone only (Meth) | 1† |
| Staff - patient ratio | 1.70 (1.14, 2.54)* |
| Prior authorization | 1.00 (0.99, 1.01) |
| Revenue from federal sources | |
| At least 1% | 1.97 (0.98, 3.90)* |
| None | 1† |
| Revenue from private insurance | |
| At least 1% | 1.35 (0.70, 2.60) |
| None | 1† |
| Year | |
| 2005 | 4.74 (2.45, 9.13)*** |
| 2011 | 1† |
A total of 313 OTPs were included in the analysis
Ninety-five percent confidence intervals estimated with robust standard errors
† Reference category; OR, Odds ratio; CI, Confidence interval
^p< 0.10. *p < 0.05. **p < 0.01. ***p < 0.001